MILONTIN Drug Patent Profile
✉ Email this page to a colleague
When do Milontin patents expire, and when can generic versions of Milontin launch?
Milontin is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in MILONTIN is phensuximide. Additional details are available on the phensuximide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MILONTIN?
- What are the global sales for MILONTIN?
- What is Average Wholesale Price for MILONTIN?
Summary for MILONTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 56 |
| Patent Applications: | 2,187 |
| DailyMed Link: | MILONTIN at DailyMed |
US Patents and Regulatory Information for MILONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | MILONTIN | phensuximide | CAPSULE;ORAL | 008855-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
